ArticleAnalytical chemistry2025
Development of a Novel Homogeneous Liposome-Based One-Step Assay for SARS-CoV-2 Antibody Detection in Human Serum Based on Fluorescent Liposomes and Complement Activity.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- His-Tag-Aptamer-Liposome-Conjugates as a Multipurpose Tool for Recombinant Protein Screening and Protein-Based Bioassays.Analytical chemistry · 2026Article
- Engineering Liposomes and Polymer Conjugates: A Platform for Mechanistic Complement Activation Studies and Controlled Release Applications.ACS applied materials & interfaces · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monitoring antibodies in patient serum enables the diagnosis of infectious and chronic diseases, the assessment of an individual's immune status, and possible protection against infection and could thus be a ubiquitous tool for pandemic preparedness and personalized medicine. Advancing from the traditional enzyme-linked immunosorbent assay (ELISA), a homogeneous assay format was developed that simplifies assay procedures and enables a wash-free one-step performance. SARS-CoV-2 was chosen as the model virus, and its Spike protein-derived receptor binding domain (RBD) was covalently coupled to fluorescent liposomes. The binding of patient antibodies triggered the complement system, led to liposome lysis, and allowed quantitative fluorescent detection. The liposome assay was optimized with respect to liposome lipid composition, RBD coverage and surface chemistry, incubation conditions, and pretreatment of a standardized complement source. A proof-of-principle was demonstrated through artificially supplemented anti-RBD antibodies and full titrations with known positive sera. Testing of 37 SARS-CoV-2 negative sera and 28 sera from individuals with SARS-CoV-2 (breakthrough) infections resulted in a specificity of 95%, sensitivity of 93% and an excellent correlation (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.